Highest-materiality recent filing
Humacyte prices $50M public offering of 47.6M shares at $1.05 per share
Sold 47,619,048 shares at $1.05/share; gross proceeds ~$50M.
ATEV patients averaged 220 catheter-free days vs 129 for AV fistula (p=0.00070), meeting superiority endpoint.
Humacyte shareholders approve increase in authorized shares to 550M at 2026 annual meeting
Authorized common stock raised from 350M to 550M shares; amendment effective June 9, 2026.
Humacyte regains Nasdaq minimum bid price compliance as of June 5, 2026
Nasdaq notified Humacyte that closing bid price was below $1.00 for 30 consecutive days as of May 1, 2026.
Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply
Received Nasdaq letter on May 4, 2026, for bid price below $1.00 for 30 consecutive business days through May 1, 2026.
Humacyte regains ex-U.S. rights to Symvess from Fresenius, pays low-single-digit royalties
Humacyte obtains sole worldwide rights to develop and commercialize Symvess; Fresenius retains U.S. distribution terms unchanged.
Humacyte reports preliminary FY2025 revenue $2M, 61 Symvess units; suspends ATM
Preliminary FY2025: cash $50.9M, total revenue $2.0M (product $1.4M), 61 Symvess unit sales.
Humacyte announces $20M registered direct offering of 25M shares at $0.80/share
Gross proceeds of $20M from 25M shares at $0.80; net proceeds ~$18.4M after fees.
Humacyte enters $60M at-the-market equity offering with TD Cowen
Up to $60M in common stock may be sold from time to time through TD Securities (USA) LLC as agent.
Humacyte terminates Revenue Interest Purchase Agreement; pays $38M cash + 5.7M shares to purchasers
Terminated Revenue Interest Purchase Agreement and Option Agreement with TPC Investments LP and Hook SA LLC as of Dec 15, 2025.
Humacyte secures up to $77.5M senior secured loan facility from Avenue; draws $40M initial tranche
Loan agreement provides $40M upfront, plus $12.5M delayed draw (Oct 2026-Mar 2027) and $25M discretionary tranche (Jul 2027-Jun 2028).
Humacyte terminates $80M at-the-market offering agreement with Jefferies
Agreement allowed sale of up to $80M in common stock via Jefferies as agent.
Total revenue $753K in Q3, all from Symvess sales; no revenue in Q3 2024.
Humacyte prices $60M registered direct offering of common stock and warrants
Raised $60.0M via sale of 28.4M shares and warrants to purchase 28.4M shares at $2.11 per unit.
Humacyte (HUMA) amends revenue interest purchase agreement; $50M repayment, discounted call option
Company to make $50.0M repayment under Purchase Agreement from restricted cash.
Revenue $0.3M in Q2 (incl $0.1M Symvess sales); $0.8M in H1 2025 vs zero prior year.
Humacyte shareholders approve authorized shares increase to 350M, elect directors
Authorized common shares raised from 250M to 350M; vote 82.6M for, 14.1M against.
Humacyte posts Q1 net income $39.1M; Symvess launch generates $147K revenue
Q1 2025 revenue $517K ($147K from first Symvess commercial sales); no revenue in Q1 2024.
Humacyte CEO: citizen petition is baseless; signatories have conflicts of interest
CEO Laura Niklason says petition signed by Robert E. Lee and Hooman Noorchashm is 'without merit'.
Humacyte posts Q4 net loss of $20.9M; Symvess commercial launch underway after FDA approval
Net loss Q4 2024 $20.9M vs $25.1M Q4 2023; full year net loss $148.7M vs $110.8M.
Humacyte CEO rebuts NYT article questioning FDA approval of Symvess
FDA took 19 extra weeks after PDUFA date, consulted three outside surgeons before approving Symvess on Dec 19, 2024.
Humacyte prices 25M-share public offering at $2.00/share, expects $50M gross proceeds
Offering of 25,000,000 shares at $2.00/share; gross proceeds ~$50M, net ~$46.6M after discounts and expenses.
Investor presentation dated March 2025 made available; content not fully disclosed in this filing.
Humacyte receives FDA full approval for SYMVESS in extremity arterial injury
FDA grants full approval for SYMVESS as a vascular conduit for extremity arterial injury when autologous vein graft is not feasible.
Humacyte prices $15M registered direct offering of common stock and warrants at $5.34/unit
Pricing of 2,808,988 shares and warrants to purchase up to 2,808,988 shares at $5.34 per unit on Nov 14, 2024.
Humacyte Q3 net loss $39.2M; ATEV BLA review ongoing with no new timeline
Net loss $39.2M (Q3 2024) vs $26.0M (Q3 2023) driven by non-cash contingent earnout remeasurement.
Humacyte ATEV meets Phase 3 co-primary endpoints; superior to AV fistula in hemodialysis
ATEV showed functional patency 81.3% at 6 months vs 66.4% for AV fistula; secondary patency 68.3% vs 62.2% at 12 months (joint p=0.0071).
Humacyte prices $30M registered direct offering of common stock and warrants at $5.28/unit
Offering of 5,681,820 common shares and 5,681,820 warrants at $5.28 per unit.
Humacyte enters $50M equity purchase agreement with Lincoln Park Capital
Company can sell up to $50M of common stock to Lincoln Park over 24 months at its discretion.
FDA delays ATEV trauma BLA review beyond PDUFA date; Q2 net loss $56.7M
FDA notified Humacyte on Aug 9 that additional time needed to complete ATEV BLA review; PDUFA date was Aug 10; no revised action date yet.
Humacyte ATEV meets Phase 3 endpoints in hemodialysis access; superiority over standard of care
ATEV showed superior functional patency at 6 months (81.3% vs 66.4%) and secondary patency at 12 months (68.3% vs 62.2%); p=0.0071.
Humacyte holds 2024 annual meeting; re-elects six directors and ratifies PwC as auditor
John P. Bamforth, Emery N. Brown, Michael T. Constantino, Keith Anthony Jones, Laura E. Niklason, Susan Windham-Bannister elected as Class III directors.
Humacyte Q1 net loss $31.9M; FDA grants Priority Review for HAV, PDUFA Aug 10, 2024
Net loss $31.9M vs $37.0M YoY; no revenue; cash $115.5M, up from $35.1M net provided.
Humacyte BLA for HAV gets Priority Review; PDUFA Aug 10, 2024; Q4 net loss $25.1M
FDA accepted BLA for HAV with Priority Review in vascular trauma; PDUFA date August 10, 2024.
Humacyte prices $40.2M public offering of 13.4M shares at $3.00 per share
Offering of 13,400,000 shares at $3.00/share; gross proceeds $40.2M before underwriting discounts.
Investor presentation made available on February 29, 2024 for use in investor calls and conferences.
FDA grants Priority Review to Humacyte's HAV BLA; PDUFA date August 10, 2024
BLA for Human Acellular Vessel in urgent arterial repair after extremity vascular trauma accepted with Priority Review.
BLA submitted to FDA seeking approval of Human Acellular Vessel (HAV) for urgent arterial repair in extremity vascular trauma.
Humacyte Q3 net loss $26M; positive V005 trauma trial results, BLA filing planned this quarter
Cash and equivalents $100M; funding from Oberland up to $160M, $40M received.
Humacyte reports positive Phase 2/3 HAV trauma trial; BLA planned Q4 2023
30-day secondary patency 90.2% (extremity pts) vs 81.1% synthetic graft benchmark.
Humacyte Q2 net loss $22.7M; vascular trauma trial enrollment complete, BLA on track
Completed enrollment in Phase 2/3 V005 trauma trial (68 patients, 51 for efficacy); top-line results expected Q3 2023.
Humacyte completes enrollment in Phase 2/3 vascular trauma trial; BLA filing planned for Q4 2023
Enrollment completed in V005 trial; 68 patients received HAV, 51 in primary efficacy analysis for extremity trauma.
Humacyte stockholders elect directors and ratify PwC as auditor at 2023 annual meeting
Elected Gordon Binder, Todd Pope, Kathleen Sebelius, Rajiv Shukla as Class II directors (term to 2026).
Humacyte Q1 net loss $37M; secures second RMAT for HAV in vascular trauma, plans BLA filing in 2023
Net loss of $37.0M in Q1 2023 vs $19.8M in Q1 2022; cash & investments $131.7M at March 31, 2023.
Humacyte nears enrollment completion in two pivotal HAV trials; cash to fund ops thru 2024
Phase 2/3 V005 trauma trial: 46 of 50 primary endpoint patients enrolled; BLA filing ~4 months after trial ends.
Humacyte reports immaterial SVB exposure; no material impact expected
Cash balance at SVB is immaterial; investment portfolio holds no SVB securities.
Humacyte amends bylaws to strengthen director nomination rules and align with Delaware law
Board approved amended bylaws effective Dec 8, 2022, adding universal proxy rule compliance requirements (Rule 14a-19).
Humacyte reports Q3 2022 net loss $25.3M, cash $171.7M, BLA filing for vascular trauma mid 2023
Cash $171.7M at Sep 30, 2022; net loss $25.3M for Q3; cash runway through 2024.
Humacyte appoints Lt. Gen. Bruce Green to board and Cindy Cao as CRO
Green, former U.S. Air Force Surgeon General, joins Board as Class I director.
Humacyte Q2 net income $36.9M driven by non-cash gains; HAVs show promise in Ukraine
Cash $189.0M as of June 30, 2022; company expects runway through 2024, past potential HAV approval in vascular trauma.
On September 15, 2022, the Board of Directors (the “Board”) of Humacyte, Inc. (the “Company”), appointed C. Bruce Green to the Board.
This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K of Humacyte, Inc. (the "Original Report"), which reported the departure of Jeffrey H. Lawson, M.D., PhD. as the Company's Chief Surgical Officer and Dr. Lawson's resignation from the Company's board of directors, each effective as of the "separation date."
This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K of Humacyte, Inc. (the "Original Report"), which reported the departure of Jeffrey H. Lawson, M.D., PhD. as the Company's Chief Surgical Officer and Dr. Lawson's resignation from the Company's board of directors, each effective as of the "separation date."
Dr. Lawson also resigned from the Company’s board of directors, effective as of the Separation Date.
On December 23, 2021, Humacyte, Inc. (the “Company”) and Jeffrey H. Lawson, M.D., Ph.D., the Company’s Chief Surgical Officer, mutually agreed to end Dr. Lawson’s employment with the Company, effective December 31, 2022 (the “Separation Date”).
Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer
Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer
Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer
Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer
Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer
Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer
Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer
Max materiality 0.90 · Median 0.68 · Most common event other_material